Farxiga is the first drug to be approved to reduce the risk for many causes of disease, including kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure.
Investigators selected patients with mild COVID-19 to receive either ivermectin or placebo to determine whether ivermectin is an efficacious treatment.
Investigators assessed how critically ill adult patients with COVID-19 and respiratory or cardiovascular organ support responded to tocilizumab or sarilumab treatments.
Patients were randomized to receive either ruxolitinib 5mg twice daily (BID) plus standard of care (SoC), ruxolitinib 15mg BID plus SoC or placebo plus SoC.
MOVe-OUT is a placebo-controlled, double-blind phase 2/3 study investigating the efficacy and safety of molnupiravir in non-hospitalized patients.
Study authors evaluated clinical trial data of people who lived in the same house as someone with COVID19 to assess if the Regeneron antibody cocktail provided protection.
The researchers wanted to collect data about the real-world effectiveness and safety of SOF/VEL in patients with chronic HCV infection and severe renal impairment.
The researchers’ objective was to determine whether machine learning-derived estimated individual corticosteroid therapy effect yields better results than treat all or treat no one strategies in adult patients with septic shock.
Study authors examined the effect of high-dose zinc and/or ascorbic acid on the severity or reduction of SARS-CoV-2 duration compared with the standard of care.
Investigators will begin an international randomized, controlled Phase 3 clinical trial to assess the safety and efficacy of an investigational long-acting antibody combination for treating patients hospitalized with COVID-19.
